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The multifunctional poly(A)-binding protein (PABP) 1 is subject to extensive
dynamic post-translational modification, which molecular modelling
suggests plays an important role in co-ordinating its activities
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PABP1 [poly(A)-binding protein 1] is a central regulator of
mRNA translation and stability and is required for miRNA
(microRNA)-mediated regulation and nonsense-mediated decay.
Numerous protein, as well as RNA, interactions underlie its multi-
functional nature; however, it is unclear how its different activities
are co-ordinated, since many partners interact via overlapping
binding sites. In the present study, we show that human PABP1
is subject to elaborate post-translational modification, identifying
14 modifications located throughout the functional domains, all
but one of which are conserved in mouse. Intriguingly, PABP1
contains glutamate and aspartate methylations, modifications of
unknown function in eukaryotes, as well as lysine and arginine
methylations, and lysine acetylations. The latter dramatically
alter the pI of PABP1, an effect also observed during the cell
cycle, suggesting that different biological processes/stimuli can
regulate its modification status, although PABP1 also probably
exists in differentially modified subpopulations within cells.
Two lysine residues were differentially acetylated or methylated,
revealing that PABP1 may be the first example of a cytoplasmic
protein utilizing a ‘methylation/acetylation switch’. Modelling
using available structures implicates these modifications in
regulating interactions with individual PAM2 (PABP-interacting
motif 2)-containing proteins, suggesting a direct link between
PABP1 modification status and the formation of distinct mRNP
(messenger ribonucleoprotein) complexes that regulate mRNA
fate in the cytoplasm.
Key words: mRNA translation, poly(A)-binding protein (PABP),
poly(A)-binding-protein-interacting motif 2 (PAM2)–poly(A)-
binding protein C-terminal domain (PABC) interaction, post-
transcriptional control, post-translational modification, RNA–
binding protein.
INTRODUCTION
Ensuring co-ordinated temporospatial and amplitudinal regu-
lation of gene expression is crucial for the control of cell
proliferation, differentiation and function. In recent years, it
has become evident that rigorous post-transcriptional control in
the cytoplasm is a major component of gene regulation: the
majority of vertebrate genes are subject to regulated mRNA
translation and/or stability [1] and their dysregulation contributes
to the aetiology of a broad spectrum of diseases [2], including
neurological, metabolic, reproductive and neoplastic disorders. In
keeping with this, diverse mRNA-specific and global regulatory
mechanisms have been described in an extensive variety of
biological contexts.
PABP [poly(A)-binding protein] 1 serves as a central regulator
of mRNA fate in the cytoplasm, co-ordinating the regulation of
mRNA utilization and destruction [3–5]. It simultaneously binds
the mRNA 3′ poly(A) tail and interacts with the translation
factor eIF (eukaryotic initiation factor) 4G, part of the cap-
binding complex eIF4F (eIF4E, eIF4G and eIF4A) [6], bringing
the ends of the mRNA into functional proximity. This ‘closed-
loop’ conformation enhances translation initiation by increasing
ribosomal recruitment while also protecting the mRNA from
deadenylation, decapping and degradation [7,8]. Contacts with
additional factors e.g. PAIP [poly(A)-interacting protein] 1 further
stabilize this closed-loop [9]. PABP1 also has other roles in
post-transcriptional regulation, both positively and negatively
regulating mRNA-specific translation and mRNA stability [3,4]
and is part of the machinery underlying miRNA (microRNA)-
mediated regulation and NMD (nonsense-mediated mRNA
decay) [8,10]. In some cases, these less well characterized roles
involve interactions with the basal translational machinery [e.g.
eIF4G, PAIP1 and eRF (eukaryotic release factor) 3], but it is clear
that additional protein and RNA interactions are also critical [3,4].
PABP1 comprises four non-identical RRMs (RNA recognition
motifs), a proline-rich region and a PABC (PABP C-terminal
domain) (also known as MLLE) and, although many binding
sites await further definition, it is clear that each domain mediates
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export motif; TOB, transducer of ERBB2; TSA, trichostatin A.
1 To whom correspondence should be addressed (email matt.brook@ed.ac.uk).
2 Present address: Tissues and Cells Directorate, Scottish National Blood Transfusion Service, 21 Ellen’s Glen Road, Edinburgh EH17 7QT, Scotland,
U.K.
3 Present address: Department of Biological Sciences, Xi’an Jiaotong-Liverpool University, Suzhou Dushu Lake Higher Education Town, China 215123
4 Present address: The Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, Scotland, U.K.
c© The Authors Journal compilation c© 2012 Biochemical Society© 2012 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
804 M. Brook and others
important functional interactions. For instance, RRMs 1 and 2
bind eIF4G and PAIP1 [3,4] and provide high-affinity
poly(A)-binding, while PABP1–PABP1 interactions mediated
by the proline-rich region also contribute to ordered binding
to poly(A) [3]. RRMs 3 and 4 bind poly(A) with reduced
affinity, but also bind AU-rich RNA and mediate protein–protein
interactions [3,4], e.g. eEF (eukaryotic elongation factor) 1α.
Finally, the PABC domain interacts with PAM (PABP-interacting
motif) 2 motif-containing proteins, e.g. eRF3, PAIP1, the negative
regulator of translation PAIP2 and the PAN [poly(A) nuclease] 3
deadenylase [9], as well as some non-PAM2-containing proteins,
e.g. the miRNA-pathway protein GW182 [11]. Thus it is unclear
how all the roles of PABP1, and the array of protein interactions
that they require, are co-ordinated. Although it seems unlikely that
PABP1 can maintain all the interactions described simultaneously,
since binding sites frequently overlap [4].
PTMs (post-translational modifications) offer a way to
dynamically regulate multifunctional proteins, and many RNA-
binding proteins, including those involved in mRNA translation,
are subject to complex regulation by phosphorylation. However,
other PTMs have also been identified on RNA-binding proteins
(e.g. lysine acetylation or arginine methylation), although their
functional consequences are less well understood. Indeed human
PABP1 is asymmetrically dimethylated on Arg455 and Arg460 in
the proline-rich region by the type I PRMT (protein arginine N-
methyltransferase) 4 [12], but the function of these PABP1 PTMs
is unknown.
In the present study we establish that PRMT4-dependent
methylation is not required for PABP1 association with
translation complexes or for its normal subcellular distribution.
However, we find that PABP1 is highly post-translationally
modified and identify 14 novel human PABP1 PTMs, including
lysine, glutamate, aspartate and PRMT4-independent arginine
methylations, as well as lysine acetylations. All, but one, are
conserved in mouse. Interestingly, the PTM status of PABP1
is dynamically regulated during the cell cycle, apparently via
modulation of lysine acetylation. Two lysine residues were both
methylated and acetylated, with structural modelling implicating
their modification status in differentially modulating key PABP1
protein interactions. This provides the first insight into how the
multiple functions of this central regulator of post-transcriptional
control may be co-ordinated.
EXPERIMENTAL
Materials
Alexa Fluor®-488- and Alexa Fluor®-546-conjugated anti-
IgG antibodies were from Invitrogen, and anti-(α-tubulin)
antibody, HRP (horseradish peroxidise)-conjugated goat anti-
rabbit IgG antibody and biochemicals were from Sigma. The
anti-PABP1 antibody has been described previously [13], and
antibodies specific for PABP1 asymmetrically dimethylated
at Arg455/Arg460 were from Mark Bedford (Department of
Carcinogenesis, University of Texas, MD Anderson Cancer
Center, Smithville, TX, U.S.A.) and Cell Signaling Technology,
and ASYM24 and SYM10 antibodies were from Millipore. HRP-
conjugated goat anti-mouse IgG, anti-GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) and anti-G3BP [Ras GAP (GTPase-
activating protein) SH3 (Src homology 3) domain-binding
protein] antibodies were from Thermo Scientific, Abcam and
Becton Dickinson respectively. Calyculin A, TSA (trichostatin
A), nocodazole and a ProteoExtract kit were from Calbiochem.
Immobilized linear pH gradient strips, ampholytes and Protein
G–Sepharose beads were from GE Healthcare.
Cell culture and synchronization, and confocal
immunofluorescence microscopy
Prmt4+ / + and Prmt4− / − MEFs (mouse embryonic fibroblasts)
and HeLa cells were cultured as described previously
[13,14] and, where required, supplemented with 400 nM TSA
(Calbiochem)/5 mM nicotinamide or 20 μM AdOX (adenosine
dialdehyde) for 24 h prior to harvest and/or 500 μM sodium
arsenite for 30 min. HeLa cells were synchronized by a double-
thymidine/nocodazole block [15]. Microscopic analyses were
carried out as described previously [13].
OFFGEL analysis
Proteins were precipitated using a ProteoExtract kit and
resolubilized into 1× OFFGEL buffer [6.8 M urea, 2 M thiourea,
62.5 mM DTT (dithiothrietol) and 5% glycerol] containing 0.5%
ampholytes. Solution-phase isoelectric focusing was performed
using 13 cm pH 6–11 or pH 3–10 immobilized linear pH gradient
strips in an Agilent 3100 OFFGEL fractionator according to the
manufacturer’s instructions. Fractions were recovered and re-
precipitated before being solubilized in an equal volume of 1×
Laemmli sample buffer [250 mM Tris/HCl (pH 6.8), 2% (w/v)
SDS, 20% (v/v) glycerol and 100 mM DTT]. Equal volumes of
each fraction were analysed by PAGE and Western blotting.
Sucrose gradient polysome analysis
If appropriate, cells were incubated in 100 μg/ml cycloheximide
for 15 min prior to harvesting in ice-cold PBS. Cells were
lysed in polysome lysis buffer [10 mM Tris/HCl (pH 7.2),
150 mM KCl, 10 mM MgCl2, 20 mM DTT, 0.5% Nonidet
P40, 100 units/ml RNasin® (Promega) and 10 nM calyculin A]
containing CompleteTM protease inhibitor cocktail (Roche) and
either 150 μg/ml cycloheximide or 20 mM EDTA, and were
incubated on ice for 10 min. Lysates were cleared for 1 min at
14000 g at 4 ◦C and the KCl concentration of the supernatant was
increased to 250 mM before applying to 10–50% (w/v) sucrose
gradients prepared in gradient buffer [10 mM Tris/HCl (pH 7.2),
250 mM KCl, 10 mM MgCl2, 2.5 mM DTT, 0.5 μg/ml heparin
and 0.5% Nonidet P40]. Gradients were centrifuged for 2 h at
38000 rev./min at 4 ◦C in a Sorval TH-641 rotor and fractionated
using a Superfrac fraction collector (Pharmacia) at 4 ◦C. The
absorbance of RNA at 254 nm was recorded by an inline UV
monitor (Pharmacia) and proteins were precipitated from fractions
using 10% trichloroacetic acid, resolubilized in 1× Laemmli
sample buffer and analysed by Western blotting.
Western blotting and immunoprecipitation
Cell extracts for Western blotting were prepared by lysing cells
in 1× Laemmli sample buffer and shearing genomic DNA by
passing lysates through Qiashredder spin columns (Qiagen).
Western blotting was performed [13] using primary antibodies
at a 1:10000 dilution or at the manufacturer’s recommended
dilution, and HRP-conjugated secondary antibodies were used
at 1:150000 (anti-rabbit IgG) or 1:20000 (anti-mouse IgG).
For immunoprecipitation, extracts were prepared by lysing
cells in immunoprecipitation lysis buffer [50 mM Tris/HCl
(pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Nonidet P40, 0.2%
SDS, 10 mM sodium pyrophosphate, 25 mM 2-glycerophosphate,
0.5% sodium deoxycholate, 10 mM sodium orthovanadate,
5 mM sodium fluoride, 2 mM DTT and 10 nM calyculin A]
containing CompleteTM protease inhibitor cocktail for 5 min on
ice. Extracts were clarified (14000 g for 10 min) and protein
supernatant concentrations were determined by the Bradford
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assay. Equal amounts of protein supplemented with either anti-
PABP1 or rabbit IgG (200 ng/mg of protein) and 60 μl of a
50% slurry Protein G–Sepharose beads were tumbled overnight
at 4 ◦C, washed extensively with immunoprecipitation lysis
buffer at 4 ◦C and eluted in 1× Laemmli sample buffer.
MS analysis
Excised colloidal Coomassie-Blue-stained protein bands were
digested with trypsin and IMAC (immobilized metal ion
chromatography) and MS samples were prepared as described
previously [16]. Full scan MS survey spectra (m/z 350–1800)
in profile mode were acquired in the orbitrap with a resolution
of 60000 after accumulation of 500000 ions. The five most
intense peptide ions from the preview scan in the Orbitrap were
fragmented by collision-induced dissociation and these ions
were rejected for 30 s after two occurrences. Precursor ion charge
state screening was enabled and all unassigned charge states,
as well as singly charged species, were rejected. The lock mass
option was enabled for survey scans to improve mass accuracy and
the data were acquired using Orbitrap 2.4 software and analysed
using Xcalibur 2.0.7 software.
Mascot generic files were created from the raw files using
raw2msm (a gift from Professor M. Mann, Max Planck Institute
of Biochemistry, Munich, Germany) and searched against
the SwissProt database using Mascot version 2.2 software
(http://www.matrixscience.com) on a local server. The search
parameters were set using trypsin as the enzyme (up to two missed
cleavages allowed), and a mass tolerance of 10 p.p.m. for the
precursor masses and 0.6 Da for the MS/MS (tandem MS) scans.
Carbamidomethylation of cysteine was set as a fixed modification,
and variable modifications included oxidation of methionine,
phosphorylation of serine, threonine or tyrosine, acetylation of
lysine, methylation of lysine, arginine, aspartate and glutamate,
and dimethylation of lysine and arginine. All but one identified
peptide had a minimum Mascot ion score of 20, and all sites
of predicted PTM were manually validated by inspection of the
MS/MS spectra.
Predictive modelling
Discovery Studio was used for molecular modelling (version
3.1, Accelrys). The PABP1 RRM4 structure was generated by
performing sequence alignment-based molecular superimposition
on to the NMR solution structure of human PABP3 RRM4
(PDB code 2D9P). The structural geometry was optimized by
application of a fast Dreiding-like forcefield using the ‘Clean
Geometry’ toolkit. This structure was superimposed on to the
crystal structure of human PABP1 RRM2 in complex with
poly(A) RNA (PDB code 1CVJ) using multiple protein tethers.
RRM4 and poly(A) relational geometries were optimized as
above. PABC–PAM2 models were based on crystal structures
PDB code 3KUS and PDB code 3KUI [17,18]. Dimethyl or
acetyl groups were added as required using Discovery Studio.
The modified molecules were energy-minimized using conjugate
gradients employing a CHARMM forcefield [19], until the root-
mean-square gradient was less than 0.0001 kcal/mol per Å
(1 Å = 0.1 nm).
RESULTS
Effect of PRMT4-dependent arginine methylation on the polysomal
association and subcellular distribution of PABP1
Loss of PRMT4 methyltransferase activity in mice leads to a
small-size phenotype and perinatal mortality [14]. As Arg455 and
Figure 1 PRMT4-dependent arginine methylation is not required for the
association of PABP1 with translation complexes or regulation of its
subcellular localization
(A) Polysomal association of PABP1 in Prmt4 + / + and Prmt4 − / − MEFs. Cell lysates were
fractionated following 10–50 % sucrose-density-gradient centrifugation in the presence ( + ) or
absence ( − ) of EDTA and immunoblotted for PABP1. Position of polysomes, 80S monosomes,
60S subunits and mRNPs are indicated. (B) Cytoplasmic localization of PABP1 and its
recruitment to SGs in Prmt4 + / + and Prmt4 − / − MEFs. MEFs were either left untreated (NT)
or treated with 500 μM sodium arsenite (Ars), and PABP1 (green) distribution was determined
by confocal microscopy. G3BP is an SG marker (red) and DNA was visualized by DAPI staining
(blue).
Arg460 of PABP1 are major targets of PRMT4 [12,14], loss of
their methylation may contribute to these phenotypes, leading
us to probe their functional role. Initially, their contribution
to the fundamental ability of PABP1 to promote translation
was addressed using MEFs from Prmt4+ / + and Prmt4− / − mice
(Supplementary Figure S1 at http://www.BiochemJ.org/
bj/441/bj4410803add.htm). As expected in Prmt4+ / + MEFs
under normal growth conditions, a significant proportion of
PABP1 was associated with actively translating mRNAs on
polysomes, although also present in mRNP fractions containing
non-translating mRNAs (Figure 1A). PABP1 was redistributed
upon disruption of polysomes with EDTA treatment. Importantly,
this pattern was maintained in Prmt4− / − MEFs (Figure 1A). Thus
although Arg455/Arg460 lie within the proline-rich region required
for co-operative high-affinity binding to poly(A) tails [3,13], the
unaltered polysomal association of PABP1 in Prmt4− / − MEFs
suggests that neither its in vivo poly(A)-binding function nor its
participation in translation complexes is significantly affected.
Reduced PABP1 half-life could also disrupt protein synthesis and
may be masked by PABP1 autoregulation [13]. However, PABP1
protein stability was not altered (Supplementary Figure S2 at
http://www.BiochemJ.org/bj/441/bj4410803add.htm), showing
that PRMT4-mediated methylation does not significantly affect
the rate of PABP1 turnover.
Although predominantly diffusely cytoplasmic, the subcellular
localization of PABP1 is subject to dynamic regulation, being
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Figure 2 PABP1 is arginine dimethylated independently of PRMT4
PABP1 was immunoprecipitated from Prmt4 + / + and Prmt4 − / − MEFs (A) or HeLa cells (B) and
Western blotted using anti-(dimethyl-Arg455/Arg460-PABP1), anti-(symmetrically dimethylated
arginine) (SYM10), anti-(asymmetrically dimethylated arginine) (ASYM24) or anti-PABP1
antibodies (A, right-hand panel; B, bottom panel). The anti-(methyl-arginine) antibodies
also detected additional methylated antigens (marked with *) in PABP1 immunoprecipitates.
Molecular mass in kDa is indicated.
relocalized to the nucleus and/or cytoplasmic SGs (stress gran-
ules) in response to specific stresses [13,20]. Although normally
growing Prmt4− / − MEFs exhibit wider morphological variation
than Prmt4+ / + MEFs in terms of cell size and shape, the predom-
inantly cytoplasmic distribution of PABP1 was not altered by the
absence of PRMT4-mediated methylation (Figure 1B). Similarly
the majority of Prmt4− / − cells exhibited normal SG formation,
with PABP1 being recruited to these foci (Figure 1B). We
therefore conclude that PRMT4-dependent methylation does not
regulate PABP1 polysome association, PABP1 stability or its sub-
cellular distribution in normally growing or arsenite-stressed cells.
PABP1 is a substrate for PRMT4-independent arginine methylation
PRMT4, and other type 1 PRMTs (PRMT1, 3, 6 and 8),
asymmetrically dimethylate arginine. In Prmt4− / − MEFs, the
amount of asymmetrically dimethylated arginine in PABP1
is dramatically decreased, but not abrogated (Figure 2A;
ASYM24, [14]), consistent with a role for other type 1
PRMTs. Since the anti-(methyl-Arg455/Arg460 PABP1) antibody
(Figure 2A) detects reduced but persistent dimethylation in
Prmt4− / − MEFs, the sites for these other type 1 PRMTs must
include one or both of these residues. In contrast, type 2
PRMTs (PRMT5, 7 and 9) catalyse symmetrical arginine
dimethylation which was not detected in PABP1 (Figure 2A;
SYM10), although readily detected in other proteins present
within input lysates (Supplementary Figure S3 at http://www.
BiochemJ.org/bj/441/bj4410803add.htm). This suggests that
PABP1 is not a Type 2 PRMT substrate in MEFs.
To determine whether PABP1 methylation status varies
between cell type/species, PABP1 methylations were probed in
HeLa cells, which are described to contain methylated PABP1
[12]. As in MEFs, PABP1 is asymmetrically dimethylated at
sites including Arg455 and/or Arg460 but, in contrast, also appears
to be subject to type 2 symmetrical arginine dimethylation at
unknown sites (Figure 2B; SYM10). Since PABP1 arginine
Figure 3 Post-translational modification of PABP1 is not restricted to
arginine methylation
(A) HeLa cells were either left untreated (Control) or treated with 20 μM AdOX. Cell extracts
were subjected to OFFGEL isoelectric fractionation using a pH 3–10 linear immobilized pH
gradient (IPG) and fractions immunoblotted for PABP1 and α-tubulin. (B) Cell extracts from
Prmt4 + / + and Prmt4 − / − MEFs were fractionated and immunoblotted as described in (A)
using a pH 6–11 gradient and GAPDH as a control. A longer exposure of the PABP1 blots is
shown to visualize low abundance highly modified forms of PABP1. (A) α-Tubulin [40] and (B)
GAPDH [41] exhibit expected pI distributions comprising unmodified and modified forms.
methylation status differs between cell types, we examined
PABP1 function in HeLa cells treated with AdOX. AdOX blocked
general arginine methylation, but did not affect PABP1 subcellular
localization or stability (Supplementary Figure S4 at http://www.
BiochemJ.org/bj/441/bj4410803add.htm), suggesting that these
basal PABP1 properties are not significantly affected by
arginine methylation. We were unable to examine the polysomal
association of PABP1 in AdOX-treated HeLa cells due to the
perturbation of polysome levels by AdOX (results not shown).
Mammalian PABP1 is highly post-translationally modified
Since the pI of unmodified human PABP1 is pH 9.52, its
distribution in HeLa cells (between ∼pH 7.6 and 10) is consistent
with multiple PTMs. This distribution was only slightly altered
following AdOX treatment (Figure 3A), indicating the presence
of PTMs other than arginine methylation. Similarly, in both
Prmt4+ / + and Prmt4− / − MEFs a small proportion of PABP1
is detected in fractions containing proteins with significantly
lower pI values (Figure 3B; e.g. fractions 1–4 represent a pI
range ∼pH 6.0–7.7). Since its pI distribution is not significantly
affected by arginine methylation, PABP1 appears to be modified
by multiple PTM species.
Identification of novel PTMs in PABP1
To identify these novel PTMs, endogenous PABP1 was
immunoprecipitated (Supplementary Figure S5 at http://www.
BiochemJ.org/bj/441/bj4410803add.htm) from HeLa cells and
analysed by MS/MS. Greater than 70% sequence coverage was
achieved using combined data from three independent biological
replicates (results not shown), and PTMs were only assigned after
manual examination of spectra from ions indicated to be modified
by Mascot version 2.2 analysis software.
A total of 14 novel human PABP1 PTMs were identified
at 12 residues (Table 1) and comprised arginine methylation,
c© The Authors Journal compilation c© 2012 Biochemical Society© 2012 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
Extensive and dynamic post-translational modification of PABP1 807
Table 1 Identified human PABP1 PTMs
Peptides identified to contain modified residues (bold) are shown. In each case the highest recorded Mascot score for the modified ( + ) peptide is given. All spectra from putative modified peptides
were subject to manual verification. Arginine can be mono- or di-methylated, lysine can be mono-, di- or tri-methylated and glutamate and aspartate are monomethylated.
Domain Amino acid Modification Peptide Mascot score
RRM1–RRM2 spacer region Lys95 Acetylation KSGVGNIFIK + (31)
RRM2–RRM3 spacer region Glu180 Methylation EAELGAR + (25)
Glu182 Methylation EAELGAR + (25)
Lys188 Acetylation AKEFTNVYIK + (33)
RRM3 Asp209 Methylation LKDLFGK + (38)
Glu239 Methylation GFGFVSFER + (44)
RRM4 Lys299 Methylation YQGVNLYVK + (43)
Lys312 Acetylation KEFSPFGTITSAK + (64)
Lys312 Dimethylation KEFSPFGTITSAK + (72)
Lys361 Dimethylation IVATKPLYVALAQR + (38)
Proline-rich linker region Arg493 Dimethylation VANTSTQTMGPRPAAAAAAATPAVR + (99)
Arg493/Arg506 Dimethylation, methylation VANTSTQTMGPRPAAAAAAATPAVR + (34)
PABC/MLLE Lys606 Acetylation SKVDEAVAVLQAHQAK + (30)
Lys606 Dimethylation SKVDEAVAVLQAHQAK + (39)
as expected, but also lysine methylation and acetylation.
Surprisingly, several methylated glutamate residues and a
methylated aspartate residue were also detected, PTM types which
are uncharacterized in eukaryotic cells. Supplementary Figure S6
(at http://www.BiochemJ.org/bj/441/bj4410803add.htm) shows
MS/MS spectra for a representative example of each type of
PTM detected. Comparative MS analyses from Prmt4+ / + and
Prmt4− / − MEFs found that all but one of the identified PTMs were
conserved in mouse, but also identified additional modifications
resulting in a total of 22 PTMs (Supplementary Table S1 at
http://www.BiochemJ.org/bj/441/bj4410803add.htm).
Novel human PABP1 methylations were detected at Arg493 and
Arg506. Intriguingly, the latter appeared to be a novel substrate
of PRMT4 and was only detected in the monomethylated state
in the context of Arg493 methylation. Conversely, in mouse
Arg493 and Arg432 were methylated in the absence of PRMT4,
consistent with the modification status observed in Figure 2(A).
Surprisingly, multiple methylated glutamate residues were present
in PABP1, with greater frequency in MEFs (ten sites) than in
HeLa cells (three sites), which may indicate species- or cell-type-
specific differences in the utilization of this PABP1 modification.
However, Glu209 in mouse PABP1 was not methylated, despite
the equivalent residue (Asp209) being methylated in human
PABP1. Intriguingly modified forms of four of the MEF-specific
methylated glutamate residues were not detectable in Prmt4− / −
MEFs (Glu66, Glu134, Glu149 and Glu564), suggesting that they
may be conferred, presumably indirectly, in a PRMT4-dependent
manner. Their absence in HeLa cells, and the results in Figure 1,
suggest that they are not required for PABP1 to participate in
translation complexes, although they may contribute to mRNA-
specific functions that only occur in some cells/processes.
Interestingly, human PABP1 contained four methylated lysine
residues (Lys299, Lys312, Lys361 and Lys606) and four acetylated
lysine residues (Lys95, Lys188, Lys312 and Lys606). Both of
these PTMs can regulate protein–protein interactions and lysine
acetylation can also regulate nucleic acid interactions, protein
localization and turnover [21,22]. These PTMs are frequently
found on regulators of chromatin remodelling and transcription,
particularly histones, although lysine methylation is of emerging
interest in cytoplasmic proteins [21]. Intriguingly, both Lys312
and Lys606 were detected in acetylated and methylated forms
in the same analyses (Supplementary Figure S6 and Table 1),
raising the possibility of complex regulation of PABP1 function.
In histones, such lysine methylation/acetylation switches specify
protein–protein interactions and are diagnostic for closed or open
chromatin conformations [23]. To the best of our knowledge,
PABP1 is the first non-histone protein to exhibit such a
methylation/acetylation switch.
Modelling the effects of lysine modification on human PABP1
protein–protein interactions
The presence of modified lysine residues within multiple
functional domains of PABP1, two of which were subject to
differential acetylation and methylation (Lys312 and Lys606), was
of significant interest, given their ability to confer divergent
functional properties. Lys606 lies within helix 5 of the 78
amino acid PABC, the only well-characterized protein interaction
domain of PABP1, with high-resolution structures resolved for
its interaction with PAM2 motif-containing proteins, including
PAIP1, PAIP2 and eRF3 [17,18,24]. Lys606 plays a critical role
in mediating the PABC–PAM2 interactions [17], suggesting that
its differential modification could serve an important regulatory
function. Thus Lys606 in its dimethylated and acetylated forms
was modelled in silico on to the structure of the PABC domain
in complex with the PAM2 motif from PAIP2 (PDB code 3KUS
[17]) (Figure 4), an interaction for which the contributions of
individual amino acid contacts are experimentally verified [25].
In the solved structure containing unmodified Lys606, a critical
leucine residue at position 3 of the 12-amino-acid PAM2 motif
projects into a hydrophobic pocket between helices 3 and 5 of the
PABC domain comprising the side chains of Met584, Ile588, Ala610,
Lys606 and Glu609. There the PAM2 Leu3 makes hydrophobic
contacts with the aliphatic portions of Lys606 and Glu609 and
the loss of these interactions reduces PABC–PAM2 affinity by
∼1000-fold [17]. Lys606 also makes salt bridges with Glu609 from
helix 5, which may help to stabilize the hydrophobic pocket
conformation (Figure 4). Modelling revealed that dimethylation
of Lys606 does not dramatically affect overall PABC conformation
but, by altering local hydrophobicity, causes a rearrangement
of interactions such that the hydrophobic pocket widens and
Lys606 no longer salt bridges with Glu609 but, rather, salt bridges
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Figure 4 Effects of Lys606 modification on PABP1 PABC–PAIP2 PAM2
interaction
Modelling of the interaction between human PABP1 PABC (green) and the PAIP2 PAM2 motif
(purple) when lysine606 is dimethylated (middle panel) or acetylated (bottom panel), based on
the structure derived using unmodified PABC (top panel). Where key residues are visualized,
they are numbered according to their position in full-length PABP1 or within the PAIP2 PAM2
motif (1–12). α-Helices of PABC are labelled α1–5. Atoms are coloured according to the
following: red, oxygen; grey, carbon; and blue, nitrogen. Hydrogen atoms are not depicted.
Where appropriate, bonds are depicted as follows: salt bridge, thick black line; hydrogen
bond, broken black line; numerical values, bond distance (in A˚) (hydrogen bonds 2.5 A˚). A
hydrophobic pocket is formed by Met584, Ile588, Ala610 (not depicted), and Lys606 and Glu609.
The hydrophobic contacts between PAM2 Leu3 and the aliphatic portions of Lys606 and Glu609
are not depicted for clarity.
with Glu592 from helix 4 (Figure 4). This may slightly weaken
the hydrophobic interaction between PAM2 Leu3 and PABC
Lys606/Glu609. However, dimethylated Lys606 is also predicted to
hydrogen bond with Ser1 of the PAM2 motif, an interaction that
does not occur with unmodified Lys606 [17]. This suggests that
Lys606 methylation may have little overall net effect or slightly
weakens this interaction, as Ser1 contributes relatively little to the
interaction relative to Leu3 [25].
In contrast, modelling supports a more profound effect of Lys606
acetylation. Structural predictions for the PAIP2 PAM2–PABC
complex containing acetylated Lys606 (Figure 4) indicate that
the hydrophobic pocket conformation and its contacts with Leu3
are retained, with Lys606 maintaining the interaction with Glu609.
However, acetylated Lys606 also mediates an additional interaction
with Glu592, thereby stabilizing the PAM2-binding surface of the
PABC domain, as well as a hydrogen bond with PAM2 Ser1.
These additional interactions are likely to enhance the PABC–
PAM2 interaction, strongly suggesting that PABP1 binding to
PAIP2 is favoured by Lys606 acetylation.
These results led us to hypothesize that Lys606 modification
status could differentially affect interactions with individual
PAM2 motifs because, while crystal structures revealed a
high degree of structural homology between complexes, they
also demonstrated local rearrangement of residue side chains
dependent on the specific PAM2 sequence [17,18,24]. We
therefore modelled the effects of Lys606 PTM on the PABC
interaction with the N-terminal eRF3 PAM2 (eRF3-N) motif as
it binds PABC with similar affinity [25] but differs at four of the
12 amino acids. Uniquely, eRF3 has a second overlapping PAM2
motif that increases the affinity of the eRF3–PABC interaction
∼3-fold [25]. The eRF3-N PAM2 motif has the critical Leu3
residue which hydrophobically contacts PABC Lys606 (PDB code
3KUI [18]) (Figure 5), but replaces the arginine and glutamine
residues at positions 1 and 2 in PAIP2, for serine and asparagine
respectively. Unlike the PAIP2–PAM2 interaction, modelling the
effect of Lys606 PTMs on the eRF3-N–PABC structure suggests
that, in the presence of eRF3-N, acetylated Lys606 cannot maintain
both salt bridges with Glu609 and, consequently, restricts access of
eRF3-N Arg1 to the PABC hydrophobic-binding surface, causing
increased flexion in the PAM2 peptide and likely reducing the
stability of the PABC–PAM2 interaction. Conversely, when Lys606
dimethylated PABC is bound to eRF3-N, one of its salt bridges
with Glu609 is lost but a new salt bridge is formed with Glu592 in
helix 3, thereby stabilizing the conformation of the hydrophobic
pocket and the hydrophobic contacts made by Leu3, favouring an
eRF3-N interaction.
Taken together these models predict that Lys606 dimethylation
and acetylation favour interaction with eRF3 and PAIP2 [or other
proteins containing highly similar PAM2 sequence (e.g. ataxin-2)]
respectively, providing mechanistic insight into the co-ordination
of multiple protein interactions with the PABC domain.
Modelling the effects of lysine modification on protein and RNA
interactions of human PABP1 RRM4
RRM4 contains a lysine residue (Lys312) that was both methylated
and acetylated, in addition to several other methylated lysine
residues (Lys299 and Lys361), suggesting potential for regulat-
ing RRM4 function. Although there is no crystal structure for
human PABP1 RRM4, a solution NMR structure for RRM4
of human tPABP (PABPc3), which differs in only one of 71
amino acids, is derived (PDB code 2D9P) allowing its use as a
template for predicting the structure of human PABP1 RRM4. Not
surprisingly, PABP1 RRM4 mapped very closely on to the tPABP
RRM4 structure (results not shown). Since RRMs bind both RNA
and proteins, the predicted human PABP1 RRM4 structure was
superimposed on to the crystal structure of RRM2 of human
PABP1 bound to RNA (PDB code 1CVJ) [26] as these RRMs
exhibit a high degree of structural similarity (Supplementary Fig-
ure S7 at http://www.BiochemJ.org/bj/441/bj4410803add.htm).
Superimposing these structures allowed the spatial positioning of
Lys312 to be modelled (Figure 6 and and Supplementary Figure
S7), showing its position at a solvent-exposed location in helix
1, part of the convex dorsal surface of RRM4 which is directly
opposite to the RNA-binding surface, placing it in an ideal position
to mediate protein–protein interactions. Indeed, the analogous
dorsal surfaces of RRMs 1 and 2 are predicted to be the site
of key PABP1 protein interactions, such as eIF4G and PAIP-
1. Interestingly, in this regard, although few protein partners
of RRM4 have been identified, both Lys312 and Lys299 directly
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Figure 5 Effects of Lys606 modification on PABP1 PABC–eRF3-N PAM2
interaction
Modelling of the interaction between human PABP1 PABC (green) and the eRF3-N PAM2 motif
(purple) when Lys606 is dimethylated (middle panel) or acetylated (bottom panel), based on the
crystal structure of unmodified PABC [18] (top panel). Key residues are numbered according
to their position in full-length PABP1 or the eRF3-N PAM2 motif (1–12). Depiction, labels and
colour scheme are as in Figure 4.
flank the core PABP1 TD-NEM (transcription-dependent nuclear
export motif) (residues 296–317) implicated in eEF1α binding
and PABP1 nucleocytoplasmic transport [27]. Thus it is tempting
to speculate that the modification of at least one of these residues
could alter protein interactions mediated by RRM4, including the
TD-NEM motif.
Intriguingly, Lys299 also lies within one of the two RNP
motifs of RRM4 which directly contact RNA. The predicted
structure of human PABP1 RRM4 reveals that Lys299, which
is analogous to Lys104 of RRM2 being at the + 4 position
of RNP2, adopts a similar spatial position within the RRM
(Figure 6). Lys104 is required for the adenine-binding specificity of
RNP2 which results from its multiple electrostatic and stacking
interactions with proximal and neighbouring bases of poly(A)
RNA [26]. Upon methylation, modelling shows that, although
the charge state of Lys299 is unaltered, the residue becomes
bulkier and more hydrophobic. This may alter the ability of
Lys299 to hydrogen bond with adenine, potentially changing the
RNA-binding characteristics of RRM4. Thus the modifications
Figure 6 Modelling the spatial positioning of lysine residues subject to
modification in human PABP1 RRM4
Predicted structure of human PABP1 RRM4 (green) in complex with poly(A) RNA (backbone,
grey; adenosine, red) showing the position of Lys299 and Lys312, based on the superimposition
of RRM4 on to the crystal structure of RRM2 in complex with poly(A) RNA [26]. Atoms are
coloured according to the following: red, oxygen; grey, carbon; and blue, nitrogen. Hydrogen
atoms are not depicted.
identified have the potential to alter both RNA and protein
interactions mediated by PABP1.
Dynamic regulation of PABP1 modification status
Interestingly, treatment of HeLa cells with TSA and nicotinamide,
which blocks lysine deacetylation, resulted in a significant
change in the proportion of PABP1 in the pI range ∼pH 5.9–
8.3 (Figure 7A). This suggests that, although apparently sub-
stoichiometric in asynchronously growing HeLa cells, lysine
acetylation could act as a major contributor to the overall charge
state of human PABP1. Thus to assess whether such changes in
PABP1 pI occur under physiological conditions, we examined
its modification status during cell division, when extensive
translational regulation is manifest [28]. In asynchronous HeLa
cells the pI of the majority of PABP1 is in the pH 8.8–10
range, as expected (Figure 7B, lanes 11 and 12). However, in
double-thymidine-synchronized S-phase HeLa cells PABP1 is
detected with a pI range ∼pH 5.9–10. The observed reduction in
PABP1 pI is further enhanced in double-thymidine/nocodazole-
synchronized G2/M-phase HeLa cells, where PABP1 is no longer
detected in the pI range ∼pH 8.8–10 with the bulk of PABP1
appearing within the pI range ∼pH 5.3–8.25, consistent with
a high level of de novo post-translational modification. Taken
together these data reveal that PABP1 is subject to complex
and dynamic post-translational modification during the mitotic
cell cycle, of which lysine acetylation may be an important
component.
DISCUSSION
PABP1 is a multifunctional protein which regulates different
facets of post-transcriptional gene expression, suggesting that
complex modulation of its RNA binding and/or protein inter-
actions are required to co-ordinate its different functions. In the
present study we have significantly advanced our understanding of
PABP1 regulation by identifying numerous modifications with the
potential to differentially alter its function. Molecular modelling
of selected modifications, support such a role.
Two residues in PABP1 were previously identified
as predominant substrates for PRMT4-dependent arginine
methylation in vivo and additional putative PRMT4-dependent
methylation was also identified [12–14]. However, the results
of the present study argue against a PABP1-mediated deficit in
global translation or change in PABP1 distribution (Figure 1)
underlying the Prmt4− / − phenotype, although it remains possible
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Figure 7 The pI of PABP1 is dynamically regulated during the cell cycle
and is modified by lysine acetylation
(A) HeLa cells were either left untreated or treated with 400 nM TSA/5 mM nicotinamide.
Cell extracts were fractionated using a pH 3–10 linear immobilized pH gradient (IPG) and
immunoblotted for PABP1 and GAPDH. (B) HeLa cells were untreated (Asynch) or synchronized
in S- or G2/M-phase and cell extracts were fractionated and immunoblotted as described in (A).
(A and B) GAPDH [41] exhibits the expected pI distribution for its unmodified and modified
forms.
that misregulation of small subsets of mRNAs may contribute.
Our understanding of such mRNA-specific functions of PABP1
is in its infancy [4].
The identification of PRMT4-independent arginine methyla-
tions, including dimethylation of Arg493 within a Gly-Xaa-Arg
motif (Supplementary Table S1 and Table 1) indicates that
PRMT1, 3 or 6 methylate PABP1 in vivo, although they failed
to do so in vitro [29]. PRMT5 can modify PABP1 in vitro
[29], and the presence of symmetrical dimethylated arginine
residues in HeLa cells suggests that PABP1 may be a bona fide
substrate of PRMT5 (Figure 2B). Intriguingly, all of the arginine
methylation sites reside within the proline-rich linker region
of PABP1 that is important for ordered high-affinity poly(A)-
binding. However, as RNA binding is crucial for polysome
association, the nuclear export of PABP1 [13] and its distribution
within the cytoplasm [13,30], these modifications do not appear
to significantly affect this function (Figure 1 and Supplementary
Figure S4). Interestingly, this region may also play a role in
mRNA-specific regulation by individual PABP proteins [5],
consistent with the idea that these modifications could modulate
protein interactions important for mRNA-specific, rather than
global, control. However, some PTMs may function to enable or
control additional modifications, rather than influencing protein
or RNA interactions directly, as there appears to be a hierarchy
among the PTMs. For instance, PRMT4-dependent methylation
of Arg506, which is in the same peptide as Arg493, is only detected
when the latter is dimethylated.
Reduced pI forms of metazoan PABP1 in two-dimensional
SDS/PAGE [31,32] have been interpreted as indicative of
potential phosphorylation, and high-throughput studies have
identified putative phospho-sites [15,33,34]. However, neither
MS analysis following titanium-oxide-mediated enrichment
for putative phosphopeptides (results not shown) nor Pro-Q
Diamond staining of immunoprecipitated PABP1 detected PABP1
phosphorylation (results not shown). Thus the dramatic effect of
lysine acetylation on the pI of PABP1 raises the possibility that
previously observed reduced-pI forms of PABP1 are due to lysine
acetylation rather than phosphorylation.
Intriguingly, PABP1 was found to be a novel methylglutamate-
and methylaspartate-containing protein (Supplementary Figure
S6 and Table 1), modifications that are well characterized for
their role in modulating chemotactic responses in prokaryotes.
Little information is available in metazoans, but human PCNA
(proliferating cell nuclear antigen) and α-enolase contain several
such modifications, which are altered in transformed cells, albeit
with unknown functional outcomes [35,36]. PABP1 appears to
be only the third such protein to be identified in humans and
the first in mouse. Both PCNA and PABP1 interact with many
protein partners, with glutamate methylation forming an attractive
candidate for regulating interactions as it confers significant
charge and hydrophobicity changes. As these PTMs are located
throughout PABP1 (Table 1 and Supplementary Table S1) they
could mediate complex modulation of PABP1 functions, although
Prmt4− / − -dependent glutamate methylations are unlikely to be
important for its basal role in global translation. Consistent with
this, the solved structure [26] of RRMs 1 and 2 bound to poly(A)
show that these residues do not contact poly(A) RNA.
PABP1 contains several modified lysine residues (Table 1 and
Supplementary Table S1). Although acetylation neutralizes the
positive charge of lysine [21,22], consistent with the dramatic
effects of TSA/nicotinamide on PABP1 pI (Figure 7), lysine
methylation has no net effect on charge, but increases its
hydrophobicity. One of the methylated lysine residues was Lys299,
which lies within RNP2 of human PABP1 RRM4 (Table 1 and
Figure 6). Although this modification type is not known to regulate
RNA binding, at this location it presents the potential to do so by
changing hydrophobicity, creating stearic hindrance or blocking
the potential for acetylation.
The identified lysine modifications may also provide
an opportunity to modify protein–protein interactions and,
intriguingly, two residues, Lys312 within RRM4 and Lys606
within the PABC domain, were subject to both methylation
and acetylation. The PABC interacts with multiple PAM2-
containing proteins, but how binding partner specificity is
conferred is unclear, despite the availability of solved structures
and identification of key interacting residues [17,18,24]. However,
modelling of Lys606 modifications on to these structures provides
initial mechanistic insight regarding the co-ordination of partner
specificity. Upon Lys606 acetylation, PABC is predicted to bind
more favourably to the PAIP2 PAM2 motif (Figure 4), but less well
than unmodified PABC to either of the two eRF3 PAM2 motifs
(Figure 5 and results not shown). Conversely upon methylation of
Lys606, PABC is predicted to provide a more favourable interaction
site for the eRF3-N PAM2 motif than when unmodified, whereas
binding of the PAIP2 PAM2 does not appear to be significantly
affected. Therefore the mutually exclusive modification of a
single residue appears to contribute to, and may be sufficient to
allow, discrimination between PAM2-containing protein partners.
Such discrimination between binding partners could facilitate the
differential roles of the PABC domain in directing PABP1 function
in such apparently diverse processes as translation initiation,
termination, mRNA stabilization and deadenylation.
Not all PABC interactions may be directly affected by Lys606
modification. GW182 does not contact Lys606 [24], although it
interacts with the same binding surface as PAM2-containing
proteins. However, by altering eRF3 affinity, Lys606 PTMs could
indirectly affect this interaction, or those of lower affinity PAM2-
containing proteins [e.g. PAN3 or TOB (transducer of ERBB2)
1] which compete with eRF3 binding in vivo [37,38]. An absence
of structural information regarding PABC–PAN3 and PABC–
TOB1 complexes precludes prediction as to whether Lys606
PTMs may also directly regulate these interactions. Nonetheless,
it is clear that a Lys606 methylation/acetylation switch could
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regulate PABP1 assembly into mRNPs with both PAM2 and
non-PAM2-containing proteins that participate in different aspects
of post-transcriptional regulation.
Most mammalian mRNAs, however, possess poly(A) tails of
sufficient length to bind several PABP molecules. This may
allow the association of an mRNA with multiple PABC-binding
proteins, with the overall PABP1 interaction status determining
the fate of that bound mRNA. It has been proposed that the relative
stoichiometry of PABC-mediated interactions is the product of
both direct binding competition and synergistic avidity effects
[24]. However, our results suggest an alternative, wherein the PTM
status of Lys606 (and other residues) may determine the relative
binding affinity of individual PABC ligands, allowing regulation
of mRNP composition and mRNA fate.
Although PABP1 probably exists in differentially modified
states within the same cell, our cell-cycle analysis suggest that
its modification status can be regulated in response to specific
biological processes and/or extracellular stimuli. Indeed, the
MS/MS analyses most likely reflect the overall modification status
of PABP1 at different points within the cell cycle and within
individual cells, as even synchronized cells contain multiple pI
forms (Figure 7B). Given that enhanced PABP1 lysine acetylation
causes changes analogous to cell cycle in PABP1 pI (Figure 7A),
it appears likely that these modifications contribute to the
dynamic cell-cycle-mediated changes in PABP pI. Such changes
could potentially function to inhibit cap-dependent translation
while maintaining translation of specific mRNAs during cell-
cycle progression [28]. However, the large numbers of lysine
acetyltransferases and deacetylases [39], for which very few
specific substrates have been identified, precludes any speculation
as to which may underlie the observed changes in PABP1 pI.
In summary, our finding that PABP1 is subject to complex and
dynamic post-translational modification provides a framework for
understanding how multiple interactions with this key regulator
of protein synthesis may be regulated to co-ordinate its numerous
roles. Our findings open novel technically challenging avenues
of research requiring the production and extensive functional
analysis of PABP1 of defined modification status. However,
the central role of PABP1 in cellular biology underscores
the importance of dissecting the functional consequences of
individual PABP1 post-translational modifications.
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The multifunctional poly(A)-binding protein (PABP) 1 is subject to extensive
dynamic post-translational modification, which molecular modelling
suggests plays an important role in co-ordinating its activities
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Figure S1 Confirmation of the PRMT4-deficient status of Prmt4 − /− MEFs
Lysates from Prmt4+ / + and Prmt4− / − MEFs were immunoblotted to detect PRMT4. As
expected, PRMT4 is readily detectable in Prmt4+ / + MEFs, but not in Prmt4− / − MEFs. PABP1
is utilized as a loading control. Molecular mass in kDa is indicated.
Figure S2 Comparison of PABP1 protein stability in Prmt4 + /+ and
Prmt4 − /− MEFs
Protein synthesis was inhibited by the addition of 15 μg/ml cycloheximide and cell extracts were
prepared either immediately (t = 0) or after the indicated times. Equal amounts of protein
were immunoblotted to determine PABP1 levels and α-tubulin was utilized as a loading control.
In both Prmt4+ / + and Prmt4− / − MEFs, PABP1 is stable for at least 8 h after inhibition
of its synthesis and remains weakly detectable after 24 h, indicating no significant role for
PRMT4-dependent methylation in regulating PABP1 protein stability.
Figure S3 Detection of methylarginine-containing proteins in Prmt4 + /+
and Prmt4 − /− MEF lysates
Input lysates from immunoprecipitations in Figure 2(A) of the main text were Western blotted with
the anti-(methyl-PABP1), SYM10 and ASYM24 anti-(methyl-arginine) antibodies. The specific
anti-(methyl-PABP1) antibody detects modified PABP1 in input lysates and the reduction in
PABP1 methylation in Prmt4− / − MEFs (left-hand panel). The SYM10 and ASYM24 antibodies
do not detect PABP1 in input lysates, although ASYM24 detects PABP1 in immunoprecipitates
(Figure 2A of the main text). Both antibodies detect numerous other methylated antigens [1],
therefore the lack of a PABP1 signal using the SYM10 antibody in Figure 2(A) of the main text is
due to the absence of symmetrically dimethylated arginine residues in PABP1. Molecular mass
in kDa is indicated.
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Figure S4 Effects of AdOX treatment of PABP1 in HeLa cells
(A) The inhibitory effects of AdOX treatment were verified by immunoblotting cell extracts (input,
left-hand panel) and immunoprecipitated PABP1 using anti-(dimethyl-Arg455/Arg460-PABP1) or
anti-PABP1 antibodies. Control immunoprecipitations were performed using purified rabbit IgG
(right-hand panel). (B) AdOX treated ( + AdOX) or untreated cells ( − AdOX) cells either received
no further treatment (NT) or were treated with 500 μM sodium arsenite (ARS), and PABP1
(green) intracellular distribution was visualized by confocal immunofluorescence microscopy.
SG formation was marked by detection of G3BP (red) and DNA was visualized by DAPI staining
(blue). This revealed that the normal nucleocytoplasmic distribution of PABP1 was unaffected
by AdOX treatment, and neither were SG formation or recruitment of PABP1 to SGs. (C) Effect
of AdOX treatment on PABP1 protein stability. Protein synthesis was inhibited by the addition of
15 μg/ml cycloheximide and cell extracts were prepared either immediately (t = 0) or after the
indicated times. Equal amounts of protein were immunoblotted to determine PABP1 levels and
α-tubulin was detected as a loading control. This showed that PABP1 was highly stable in HeLa
cells and that AdOX treatment did not result in a reproducible effect on PABP1 protein stability.
Figure S5 Specific immunoprecipitation of PABP1 for detection of
methylated arginine residues and for MS
PABP1 was immunoprecipitated from cell lysate (input, left-hand panel) using anti-PABP1 or
normal rabbit IgG (Ctrl) antibodies. Immunoprecipitates (IP) were validated for specificity by
Western blotting for PABP1 (middle panel). For MS studies, immunoprecipitated PABP1 was
visualized by GelCode Coomassie Blue staining and the ∼73 kDa PABP1 band was excized
for analysis. A representative immunoprecipitation from Prmt4 + / + MEFs is shown. HC, heavy
chain, LC, light chain. Molecular mass in kDa is indicated.
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Extensive and dynamic post-translational modification of PABP1
Figure S6 Representative MS/MS spectra for post-translationally modified peptides identified in human PABP1
MS/MS spectra acquired on an LTQ-orbitrap LC-MS system were searched using Mascot version 2.2 allowing for various PTMs of arginine, lysine, serine, threonine, tyrosine, aspartate and glutamate
residues. MS/MS spectra matching selected PABP1 tryptic peptides, each with an ion score greater than 38 (See Table 1 of the main text), were assigned and contained the following PTMs (evidence
from ion series) (A) acetylated Lys312 (b2 ion = m/z 300.15; acetyl-KE), (B) dimethylated Lys312 (b2 = m/z 286.1; dimethyl-KE), (C) dimethylated Arg493, (D) methylated Glu239 (b8 − b7 ion = 143
Da; methylglutamate), (E) methylated Asp209 (y5 − y4 = 143 Da; methylaspartate).
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Figure S7 Modelling of human PABP1 RRM4
The structure of human PABP1 RRM4 (top right-hand panel) was modelled based on the
structure of human tPABP RRM4 (PDB code 2D9P). The predicted structure of RRM4 was
compared with the crystal structure of human PABP1 RRM2 (top left-hand panel) (PDB code
1CVJ) by superimposition (bottom; green, RRM2; red, RRM4). Ribbon models of the two separate
RRMs are shown colour-coded for secondary structure type (cyan, β-sheet; red, α-helix; white,
coil; green, turn). This shows that the predicted structure of human PABP1 RRM4 is highly
similar to the solved structure of human PABP1 RRM2 and validates the use of the RRM2
structure for predicting the spatial position of modified residues in RRM4.
Table S1 Table of PTMs identified in mouse PABP1
Peptides identified to contain modified residues (bold) are shown. In each case the highest recorded Mascot score for the modified ( + ) peptide is given. Where the modified peptide was not detected,
the presence of the unmodified ( − ) peptide is recorded. All spectra from putative modified peptides were subject to manual verification. Blank domain column entries indicate that the residue is
situated within the respective inter-RRM spacer region. PTMs not detected in human PABP1 are in italics. *, ion scored below Mascot cut-off score of 20 but was manually verified.
Mascot score
Domain Amino acid Modification Peptide Prmt4 + / + MEFs Prmt4 − / − MEFs
RRM1 Glu66 Methylation SLGYAYVNFQQPADAER + (93) − (88)
RRM1–RRM2 spacer region Lys95 Acetylation KSGVGNIFIK + (29) + (29)
RRM2 Glu134 Methylation VVCDENGSK + (58) − (22)
Glu149 Methylation GYGFVHFETQEAAER + (79) − (96)
RRM2–RRM3 spacer region Glu180 Methylation EAELGAR + (26) + (21)
Glu182 Methylation EAELGAR + (26) + (21)
Lys188 Acetylation AKEFTNVYIK + (28) + (29)
RRM3 Glu205 Methylation NFGEDMDDER + (51) + (47)
Glu239 Methylation GFGFVSFER + (50) + (58)
RRM4 Lys299 Methylation YQGVNLYVK + (44) + (46)
Glu308 Methylation NLDDGIDDER + (60) + (58)
Lys312 Acetylation EFSPFGTITSAK + (65) + (62)
Lys312 Dimethylation KEFSPFGTITSAK − (81) + (85)
Glu345 Methylation GFGFVCFSSPEEATK + (55) + (22)
Lys361 Acetylation IVATKPLYVALAQR + (22) + (25)
Lys361 Dimethylation IVATKPLYVALAQR − (87) + (99)
Proline-rich linker region Arg432 Methylation AAYYPPSQIAQLRPSPR + (17)* + (39)
Arg493 Dimethylation VANTSTQTMGPRPAAAAAAATPAVR + (74) + (80)
Arg493/Arg506 Dimethylation, methylation VANTSTQTMGPRPAAAAAAATPAVR + (52) − (80)
PABC/MLLE Glu564 Methylation QMLGER + (24) − (30)
Lys606 Acetylation SKVDEAVAVLQAHQAK + (26) + (31)
Lys606 Dimethylation SKVDEAVAVLQAHQAK − (90) + (42)
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